Chronic degenerative conditions as risk factors for lethal COVID-19

被引:2
作者
Correa, Maria Guadalupe Angeles [1 ]
Rios, Enrique Villarreal [1 ]
Rodriguez, Liliana Galicia [1 ]
Daza, Emma Rosa Vargas [1 ]
Vazquez, Gabriel Frontana [1 ]
Amaro, Sergio Javier Monrroy [1 ]
Pinal, Viridiana Ruiz [1 ]
Alvarez, Javier Davalos [1 ]
Beltran, Shaid Santibanez [1 ]
机构
[1] Inst Mexicano Seguro Social, Ciudad De Queretaro, Mexico
来源
REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH | 2022年 / 46卷
关键词
COVID-19; SARS-CoV-2; risk; mortality; chronic disease; Mexico; MORTALITY; OUTCOMES;
D O I
10.26633/RPSP.2022.40
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective. To determine the relative risk of a lethal outcome associated with chronic degenerative conditions in patients with COVID-19. Methods. A cohort study was conducted using electronic medical records belonging to patients who tested positive for COVID-19 on RT-PCR while receiving care as outpatients or inpatients in a social security system facility between March 2020 and March 2021. Two study groups were formed. The exposed group was divided into four subgroups, each of which was diagnosed with one and only one chronic condition (diabetes, hypertension, obesity, or chronic kidney disease); the unexposed group was obtained from the medical records of patients without comorbidities. A total of 1 114 medical records were examined using simple random sampling. Once the minimum sample size was reached, the relative risk was calculated for each chronic condition. Combinations of two, three, and four conditions were created, and each of them was included in the analysis. Results. In the absence of a chronic degenerative condition, the prevalence of a lethal outcome from COVID-19 is 3.8%; in the presence of type 2 diabetes mellitus, 15.8%; in the presence of arterial hypertension, 15.6%; and in the presence of obesity, 15.0%. For diabetes and hypertension combined, the prevalence of a lethal outcome is 54.1%; for diabetes and obesity combined, 36.8%, and for obesity and hypertension combined, 28.1%. Conclusion. In patients with COVID-19, the relative risk of a lethal outcome is 4.17 for those with diabetes, 4.13 for those with hypertension, and 3.96 for those with obesity. For two chronic conditions combined, the relative risk doubles or triples. The relative risk of a lethal outcome is 14.27 for diabetes plus hypertension; 9.73 for diabetes plus obesity, and 7.43 for obesity plus hypertension. Chronic conditions do not present alone; they generally occur together, hence the significance of the relative risks for lethal outcomes presented in this paper.
引用
收藏
页数:8
相关论文
共 31 条
  • [1] [Anonymous], 2012, Dementia: A Public Health Priority, P5
  • [2] Arterial hypertension
    Brouwers, Sofie
    Sudano, Isabella
    Kokubo, Yoshihiro
    Sulaica, Elisabeth M.
    [J]. LANCET, 2021, 398 (10296) : 249 - 261
  • [3] Del Aguila MJ, 2020, REV ESP SALUD PUBLIC, V6, P1
  • [4] Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy
    Grasselli, Giacomo
    Greco, Massimiliano
    Zanella, Alberto
    Albano, Giovanni
    Antonelli, Massimo
    Bellani, Giacomo
    Bonanomi, Ezio
    Cabrini, Luca
    Carlesso, Eleonora
    Castelli, Gianpaolo
    Cattaneo, Sergio
    Cereda, Danilo
    Colombo, Sergio
    Coluccello, Antonio
    Crescini, Giuseppe
    Molinari, Andrea Forastieri
    Foti, Giuseppe
    Fumagalli, Roberto
    Iotti, Giorgio Antonio
    Langer, Thomas
    Latronico, Nicola
    Lorini, Ferdinando Luca
    Mojoli, Francesco
    Natalini, Giuseppe
    Pessina, Carla Maria
    Ranieri, Vito Marco
    Rech, Roberto
    Scudeller, Luigia
    Rosano, Antonio
    Storti, Enrico
    Thompson, B. Taylor
    Tirani, Marcello
    Villani, Pier Giorgio
    Pesenti, Antonio
    Cecconi, Maurizio
    [J]. JAMA INTERNAL MEDICINE, 2020, 180 (10) : 1345 - 1355
  • [5] Diabetes is a risk factor for the progression and prognosis of COVID-19
    Guo, Weina
    Li, Mingyue
    Dong, Yalan
    Zhou, Haifeng
    Zhang, Zili
    Tian, Chunxia
    Qin, Renjie
    Wang, Haijun
    Shen, Yin
    Du, Keye
    Zhao, Lei
    Fan, Heng
    Luo, Shanshan
    Hu, Desheng
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2020, 36 (07)
  • [6] James SL, 2018, LANCET, V392, P1789, DOI [10.1016/s0140-6736(18)32335-3, 10.1016/S0140-6736(18)32335-3]
  • [7] Johns Hopkins University of Medicine, 2021, COR RES CTR MORT AN
  • [8] Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues
    Li, Meng-Yuan
    Li, Lin
    Zhang, Yue
    Wang, Xiao-Sheng
    [J]. INFECTIOUS DISEASES OF POVERTY, 2020, 9 (01)
  • [9] [李仲平 Li Zhongping], 2020, [中国软科学, China Soft Science], P1
  • [10] Latin american consensus on hypertension in patients with diabetes type 2 and metabolic syndrome
    Lopez-Jaramillo, Patricio
    Sanchez, Ramiro A.
    Diaz, Margarita
    Cobos, Leonardo
    Bryce, Alfonso
    Parra-Carrillo, Jose Z.
    Lizcano, Fernando
    Lanas, Fernando
    Sinay, Isaac
    Sierra, Ivan D.
    Penaherrera, Ernesto
    Benderky, Mario
    Schmid, Helena
    Botero, Rodrigo
    Urina, Manuel
    Lara, Joffre
    Foos, Milton C.
    Marquez, Gustavo
    Harrap, Stephen
    Ramirez, Agustin J.
    Zanchetti, Alberto
    [J]. CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2014, 26 (02): : 85 - 103